About Stromedix
Stromedix is a Healthcare company based in Cambridge (United States) founded in 2006, and was acquired by Biogen in February 2014. Drugs for fibrosis and organ failure are developed by Stromedix. Stromedix has raised $26 million across 3 funding rounds from investors including Bessemer Venture Partners, Biogen and New Leaf Venture Partners. Stromedix offers products and services including Virtual Classroom Platform. Its focus areas include Life Sciences, Immunology, Drugs and Fibrosis. Its legal entity is Stromedix Inc. Its competitors include BigHat, Kodiak Sciences and Visterra; 3 of its 3 listed competitors have raised funding.
Company details
Stromedix was founded in 2006 in Cambridge, United States, as a biomedical company. Focus is placed on developing drugs targeting fibrosis and organ failure. The lead product, STX-100, is a humanized monoclonal antibody applied to idiopathic pulmonary fibrosis. The company was acquired by Biogen in 2012 for 562 million, following an initial out-licensing of Biogens fibrosis program to Stromedix in 2006.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website stromedix.com
- Social X
- Acquired by Biogen (Feb 2014)
- Legal Name Stromedix Inc
- Total Equity Funding$26M (USD)
in 3 rounds
- Latest Funding Round$2M (USD), Debt – Conventional
Jan 2011
- InvestorsBessemer Venture Partners
& 5 more
- Acquired byBiogen
(Feb 2014)
Products & Services of Stromedix
Stromedix offers a comprehensive portfolio of products and services, including Virtual Classroom Platform.
Platform for online learning management and virtual classes
Funding Insights of Stromedix
Stromedix has successfully raised a total of $26M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2 million completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26M
- Total Rounds 3
- Last Round Debt – Conventional — $2M
- First Round $1M
(Mar 2007)
- Investors Count 5
All 3 funding rounds of Stromedix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2011 | $2M | Debt – Conventional | – | – | – |
| Apr 2008 | $25M | Series B | – | – | |
| Mar 2007 | $1M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in Stromedix
Stromedix has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Bessemer Venture Partners, Biogen and New Leaf Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture capital firm investing in life sciences companies | redabbey.com | Baltimore, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States |
Investor details for Stromedix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Stromedix
4 dated milestones of Stromedix across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Stromedix is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Debt – Conventional, of $2.0M.
- Exit Acquired by Biogen.
Competitors of Stromedix
Stromedix has 3 listed competitors in our database, 3 of them funded. They include BigHat, Kodiak Sciences and Visterra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | Antibody therapies are developed through machine learning and synthetic biology. | ||
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases |
Detailed competitors of Stromedix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Stromedix (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stromedix
Complete news archive for Stromedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stromedix
Stromedix was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Stromedix is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Stromedix is a funded company, having raised a total of $26M across 3 funding rounds to date. The company's 1st funding round was a Series A of $1M, raised on Mar 2007.
Stromedix was founded in 2006 in Cambridge, United States, as a biomedical company. Focus is placed on developing drugs targeting fibrosis and organ failure. The lead product, STX-100, is a humanized monoclonal antibody applied to idiopathic pulmonary fibrosis. The company was acquired by Biogen in 2012 for 562 million, following an initial out-licensing of Biogens fibrosis program to Stromedix in 2006.
Stromedix's top competitors include Kodiak Sciences, Visterra and BigHat.
Stromedix offers Virtual Classroom Platform.
Stromedix has 6 investors. Key investors include Bessemer Venture Partners, Biogen, New Leaf Venture Partners, Frazier Healthcare Partners, and Atlas Venture.
Stromedix operates through Stromedix Inc.
Yes. Stromedix was acquired by Biogen in February 2014.